| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
|
|
|
|
|||||||||||||
|
|
|||||||||||||||
a Federal University of
Minas Gerais, Belo Horizonte, Brazil: Unit of Paediatric
Endocrinology, b Department of
Paediatrics, c Department of Medicine, Federal
University of São Paulo, Brazil
Correspondence to: Dr I N Silva, Department of Paediatrics, Faculty of Medicine, Federal University of Minas Gerais, Avenue Alfredo Balena 190, 30130-100 Belo Horizonte, MG, Brazil.
Accepted 5 June 1997
The influence of 15 or 25 mg/m2 of daily oral
hydrocortisone with fludrocortisone 0.1 mg/day on growth and laboratory
findings was evaluated in a prospective randomised crossover trial over 12 months in 26 children with 21-hydroxylase deficiency. Nine non-salt
losers had fludrocortisone stopped for a further six month period.
Height velocity was significantly decreased during treatment with 25 mg/m2 as compared with 15 mg/m2. This was the
most sensitive indicator of corticosteroid treatment excess. A dose
dependent effect upon plasma concentrations of 17-hydroxyprogesterone,
testosterone, and androstenedione was found but increased values
were still detected in more than half of the determinations made during
the 25 mg/m2 period. Height velocity and
17-hydroxyprogesterone concentrations were positively correlated.
Growth hormone response to clonidine stimulation and insulin-like
growth factor-1 concentrations were both within reference values and
there was no difference between treatment periods. Withdrawal of
fludrocortisone did not result in any difference for the non-salt
losers. It was concluded that 25 mg/m2 of hydrocortisone
depressed growth in children with congenital adrenal hyperplasia, and
that full suppression, or even normalisation, of plasma concentrations
of 17-hydroxyprogesterone and androgens should not be considered a
treatment goal, but instead an indication of corticosteroid treatment excess.
This article has been cited by other articles:
|
|
 |
|
  Z. Chakhtoura, A. Bachelot, D. Samara-Boustani, J.-C. Ruiz, B. Donadille, J. Dulon, S. Christin-Maitre, C. Bouvattier, M.-C. Raux-Demay, P. Bouchard, et al. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur. J. Endocrinol., June 1, 2008; 158(6): 879 - 887. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. I. Shulman, G. L. Francis, M. R. Palmert, E. A. Eugster, and for the Lawson Wilkins Pediatric Endocrine Society Use of Aromatase Inhibitors in Children and Adolescents With Disorders of Growth and Adolescent Development Pediatrics, April 1, 2008; 121(4): e975 - e983. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. M. L. Stikkelbroeck, B. A. E. van't Hof-Grootenboer, A. R. M. M. Hermus, B. J. Otten, and M. A. van't Hof Growth Inhibition by Glucocorticoid Treatment in Salt Wasting 21-Hydroxylase Deficiency: In Early Infancy and (Pre)Puberty J. Clin. Endocrinol. Metab., August 1, 2003; 88(8): 3525 - 3530. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. F. Collett-Solberg Congenital Adrenal Hyperplasia: From Genetics and Biochemistry to Clinical Practice, Part 2 Clinical Pediatrics, March 1, 2001; 40(3): 125 - 132. [Abstract] [PDF]
|
|
|
|
 |
|
 P. C. White and P. W. Speiser Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency Endocr. Rev., June 1, 2000; 21(3): 245 - 291. [Abstract] [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| ARCH DIS CHILD | FETAL NEONATAL ED | ED PRACTICE |
